Pacira BioSciences, Inc. (NASDAQ:PCRX) Director Marcelo Bigal Purchases 1,512 Shares

Pacira BioSciences, Inc. (NASDAQ:PCRX) Director Marcelo Bigal acquired 1,512 shares of the stock in a transaction dated Friday, August 16th. The stock was acquired at an average price of $13.25 per share, for a total transaction of $20,034.00. Following the completion of the acquisition, the director now directly owns 10,142 shares of the company’s stock, valued at $134,381.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Pacira BioSciences Price Performance

Shares of PCRX opened at $13.85 on Thursday. The company has a market cap of $644.66 million, a price-to-earnings ratio of 9.69 and a beta of 0.88. Pacira BioSciences, Inc. has a 1-year low of $11.16 and a 1-year high of $38.23. The company’s fifty day simple moving average is $21.38 and its 200 day simple moving average is $26.33. The company has a current ratio of 6.82, a quick ratio of 5.70 and a debt-to-equity ratio of 0.67.

Pacira BioSciences (NASDAQ:PCRX) last released its quarterly earnings data on Tuesday, July 30th. The company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.53 by $0.11. Pacira BioSciences had a net margin of 9.21% and a return on equity of 13.22%. The firm had revenue of $178.02 million for the quarter, compared to the consensus estimate of $173.31 million. On average, research analysts forecast that Pacira BioSciences, Inc. will post 2.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Needham & Company LLC lowered their price objective on shares of Pacira BioSciences from $43.00 to $22.00 and set a “buy” rating on the stock in a report on Monday, August 12th. Royal Bank of Canada downgraded shares of Pacira BioSciences from an “outperform” rating to a “sector perform” rating and lowered their price objective for the company from $37.00 to $14.00 in a report on Monday, August 12th. HC Wainwright lowered their price objective on shares of Pacira BioSciences from $57.00 to $39.00 and set a “buy” rating on the stock in a report on Monday, August 12th. StockNews.com downgraded shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a report on Monday, August 12th. Finally, Raymond James downgraded shares of Pacira BioSciences from an “outperform” rating to a “market perform” rating in a report on Monday, August 12th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Pacira BioSciences presently has a consensus rating of “Hold” and a consensus price target of $24.78.

Hedge Funds Weigh In On Pacira BioSciences

Several institutional investors and hedge funds have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Pacira BioSciences by 5.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,973 shares of the company’s stock valued at $741,000 after acquiring an additional 1,186 shares during the period. Louisiana State Employees Retirement System bought a new stake in shares of Pacira BioSciences in the fourth quarter valued at about $783,000. abrdn plc boosted its position in shares of Pacira BioSciences by 14.3% in the fourth quarter. abrdn plc now owns 448,691 shares of the company’s stock valued at $15,139,000 after acquiring an additional 56,081 shares during the period. Duality Advisers LP boosted its position in shares of Pacira BioSciences by 4.9% in the fourth quarter. Duality Advisers LP now owns 34,179 shares of the company’s stock valued at $1,153,000 after acquiring an additional 1,591 shares during the period. Finally, Wedge Capital Management L L P NC bought a new stake in shares of Pacira BioSciences in the fourth quarter valued at about $1,060,000. 99.73% of the stock is currently owned by institutional investors and hedge funds.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.